Nearly 3.2 million seniors will lose their Medicare Advantage plans in 2027 as insurers withdraw from hundreds of counties to protect profits. This reduction means fewer plan options, higher out-of-pocket costs, and changes in provider networks, making it harder for seniors to find affordable, comprehensive coverage. The average in-network medical spending limit and prescription drug deductibles are rising, increasing overall healthcare expenses despite sometimes lower premiums. Seniors must carefully compare replacement plans before the December 7 enrollment deadline, while investors should watch insurers' profitability amid these market shifts.
The story about 3.2 million seniors losing their Medicare Advantage plans in 2027 is presented here with Pluang's Health-sector market data as of Oct 19, 2026 20:02 WIB. Of 150 priced US Health-sector stocks tradable on Pluang, 62 rose and 66 fell today. Notable movers include TWST (Twist Bioscience Corp) at USD 135.80 with a 1-day change of +2.30%, IOVA (Iovance Biotherapeutics Inc. Common Stock) at USD 13.88 with +1.91%, and RXRX (Recursion Pharmaceuticals Inc) at USD 3.53 with +1.88%.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
